Archive for September 29, 2008

Serogroup A Neisseria meningitidis with Reduced Susceptibility to Ciprofloxacin

Emerging Infectious Diseases  October 2008  V.14  N.10

Letter

Jacob Strahilevitz, Amos Adler, Gillian Smollan, Violeta Temper, Nathan Keller, and Colin Block

Hadassah-Hebrew University Medical Center, Jerusalem, Israel (J. Strahilevitz, A. Adler, V. Temper, C. Block); and The Chaim Sheba Medical Center, Tel Hashomer, Israel (G. Smollan, N. Keller)

FREE Full Text
http://www.cdc.gov/eid/content/14/10/1667.htm

PDF
http://www.cdc.gov/eid/content/14/10/pdfs/1667.pdf

September 29, 2008 at 5:47 pm Leave a comment

Confirmed Mycoplasma pneumoniae Endocarditis

Emerging Infectious Diseases  October 2008  V.14  N.10

Letter
Juan Pablo Scapini,  Luis Pedro Flynn, Silvia Sciacaluga, Lorena Morales, and María Estela Cadario

Facultad de Ciencias Médicas Universidad Nacional de Rosario, Santa Fe, Argentina (J.P. Scapini); Sanatorio de Niños Rosario, Santa Fe, (L.P. Flynn; S. Sciacaluga, L. Morales); and Instituto Nacional de Enfermedades Infecciosas ANLIS “Dr Carlos Malbrán,” Buenos Aires, Argentina (M.E. Cadario)

FREE Full Text
http://www.cdc.gov/eid/content/14/10/1664.htm

PDF
http://www.cdc.gov/eid/content/14/10/pdfs/1664.pdf

September 29, 2008 at 5:46 pm Leave a comment

Prophylaxis after Exposure to Coxiella burnetii

Emerging Infectious Diseases  October 2008  V.14  N.10

Claire E. Moodie,  Herbert A. Thompson, Martin I. Meltzer, and David L. Swerdlow

Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Abstract
Coxiella burnetii is a category B bioterrorism agent. We numerically evaluated the risks and benefits from postexposure prophylaxis (PEP) after an intentional release of C. burnetii to the general population, pregnant women, and other high-risk populations. For each group, we constructed a decision tree to estimate illness and deaths averted by use of PEP/100,000 population. We calculated the threshold points at which the number of PEP-related adverse events was equal to the cases averted. PEP was defined as doxycycline (100 mg 2×/day for 5 days), except for pregnant women, where we assumed a PEP of trimethoprim-sulfamethoxazole (160 mg/800 mg 2×/day) for the duration of the pregnancy. PEP would begin 8–12 days postexposure. On the basis of upper-bound probability estimates of PEP-related adverse events for doxycycline, we concluded that the risk for Q fever illness outweighs the risk for antimicrobial drug–related adverse events when the probability of C. burnetii exposure is >7% (pregnant women using trimethoprim-sulfamethoxazole = 16%).

FREE Full Text
http://www.cdc.gov/eid/content/14/10/1558.htm

PDF
http://www.cdc.gov/eid/content/14/10/pdfs/1558.pdf

September 29, 2008 at 5:44 pm Leave a comment


Calendar

September 2008
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  

Posts by Month

Posts by Category